| 2025-04-22 | +2.13 % |
|
| 2025-04-21 | -1.64 % |
|
| 2025-04-17 | +0.76 % |
|
| 2025-04-16 | -2.9 % |
|
| 2025-04-15 | -1.28 % |
|
| 2025-04-14 | +2.31 % |
|
| 2025-04-11 | +0.49 % |
|
| 2025-04-10 | -3.14 % |
|
| 2025-04-09 | +2.37 % |
|
| 2025-04-08 | -5.83 % |
|
| 2025-04-07 | -0.22 % |
- AbbVie (ABBV) stock experienced a decline of -0.22% due to potential investor concerns stemming from allegations of misleading statements related to the merger with Cerevel Therapeutics, where it is claimed that involved parties, including Bain Capital and Pfizer, may have acted unlawfully during a secondary stock offering.
- AbbVie (ABBV) stock experienced a decline of 0.22% amid trading, falling to $193.97, likely influenced by its trading volume being lower than average and the overall market dynamics affecting biotechnology stocks.
- AbbVie (ABBV) stock fell by 0.22%, closing at $186.58 amid higher trading volumes, likely influenced by broader market trends affecting pharmaceutical stocks, including competition and regulatory factors present within the industry.
- AbbVie (ABBV) stock declined by 0.22% to $186.58 amidst notable trading activity and performance metrics indicating vulnerability in its financial ratios, suggesting investor uncertainty and market volatility related to its products and earnings potential.
- AbbVie (ABBV) stock fell by 0.22% amid a broader trend of declining prices among major companies in the dividend stock sector, specifically experiencing a drop of $15.06 to $186.58 during trading hours. The decline may be attributed to overall market movements and investor sentiment affecting the stock's trading volume and performance in relation to its 50-day and 200-day moving averages.
|
| 2025-04-02 | -0.52 % |
|
| 2025-04-01 | -1.55 % |
|
| 2025-03-31 | +2.06 % |
|
| 2025-03-27 | +0.71 % |
|
| 2025-03-26 | -0.02 % |
|
| 2025-03-25 | -3.74 % |
|
| 2025-03-24 | -0.4 % |
|
| 2025-03-21 | -0.92 % |
|
| 2025-03-20 | -0.14 % |
|
| 2025-03-19 | -0.75 % |
|
| 2025-03-18 | -0.29 % |
|
| 2025-03-14 | +0.1 % |
|
| 2025-03-13 | -0.24 % |
|
| 2025-03-12 | -0.72 % |
|
| 2025-03-11 | -1.42 % |
|
| 2025-03-10 | +1.11 % |
|
| 2025-03-07 | +1.68 % |
|
| 2025-03-06 | -0.37 % |
|
| 2025-03-04 | -1.76 % |
|
| 2025-02-27 | +0.99 % |
|
| 2025-02-26 | -0.55 % |
|
| 2025-02-25 | +0.03 % |
|
| 2025-02-21 | +0.6 % |
|
| 2025-02-18 | +1.75 % |
|
| 2025-02-12 | +0.61 % |
|
| 2025-02-11 | +0.78 % |
|
| 2025-02-07 | -1.23 % |
|
| 2025-02-06 | +0.64 % |
|
| 2025-02-05 | +0.95 % |
- AbbVie (ABBV) stock increased by 0.95% following a price target raise from Guggenheim from $212.00 to $214.00, along with several other analysts upgrading their ratings and target prices, suggesting strong investor confidence in the stock's potential.
- AbbVie (ABBV) stock rose by 0.95% after analysts at Raymond James reaffirmed their "outperform" rating and increased the target price from $218.00 to $220.00, indicating a potential upside, while a consensus of analysts maintains a "Moderate Buy" rating on the stock.
- AbbVie (ABBV) stock rose by 0.95% following Jim Cramer's endorsement on "Mad Money," where he highlighted the company's potential and success with its immunosuppressive drugs, suggesting it's undervalued despite recent declines.
The stock's increase can be attributed to positive analyst sentiment, particularly from Cramer, and AbbVie's strong performance in the biopharma sector, especially with its drugs Skyrizi and Rinvoq, providing reassurance to investors amid market uncertainties.
- AbbVie (ABBV) stock rose 0.95% following a target price increase from Truist Financial from $211.00 to $217.00, reflecting a positive outlook and a "buy" rating by the brokerage.
- AbbVie (ABBV) stock increased by 0.95% after UBS Group raised its price target from $181.00 to $190.00, indicating continued positive analyst sentiment toward the company's future performance despite a recent earnings miss.
|
| 2025-02-04 | -0.1 % |
|
| 2025-02-03 | +3.39 % |
|
| 2025-01-31 | +4.7 % |
|
| 2025-01-28 | -1.18 % |
|
| 2025-01-27 | +3.88 % |
|
| 2025-01-24 | -0.22 % |
|
| 2025-01-23 | +0.87 % |
|
| 2025-01-22 | -1.98 % |
|
| 2025-01-17 | -1.23 % |
|
| 2025-01-16 | +1.37 % |
|
| 2025-01-15 | -2.39 % |
|
| 2025-01-13 | +0.9 % |
|
| 2025-01-10 | -1.87 % |
|
| 2025-01-06 | -0.62 % |
|
| 2025-01-03 | +0.99 % |
- AbbVie Inc. (NYSE:ABBV) saw its stock rise by 0.99% last night due to increased institutional investor holdings and positive analyst ratings, despite some mixed views on its stock performance.
The stock rose primarily because institutional investors, like Old Port Advisors, have been increasing their holdings, signaling confidence in AbbVie's potential, alongside favorable analyst ratings and an increase in their quarterly dividend.
- AbbVie Inc. (ABBV) stock rose by 0.99% following a significant increase in institutional investments, particularly from Versant Capital Management Inc, which raised its holdings in the company by 33.9% during the fourth quarter, along with positive earnings results and a favorable dividend announcement.
- AbbVie (ABBV) stock rose 0.99% due to increased institutional investment, positive quarterly earnings results that exceeded estimates, and a recently announced dividend hike, contributing to a favorable outlook from analysts.
|
| 2025-01-02 | +0.98 % |
|
| 2024-12-30 | -1.02 % |
|
| 2024-12-26 | -0.44 % |
|
| 2024-12-20 | +2.37 % |
|
| 2024-12-19 | -0.87 % |
|
| 2024-12-18 | -1.35 % |
|
| 2024-12-17 | +2.18 % |
|
| 2024-12-16 | -1 % |
|
| 2024-12-12 | -0.68 % |
|
| 2024-12-10 | -0.51 % |
|
| 2024-12-06 | +0.01 % |
|
| 2024-12-02 | -0.63 % |
|
| 2024-11-29 | -0.08 % |
|
| 2024-11-27 | +1.07 % |
|
| 2024-11-25 | +0.06 % |
|
| 2024-11-21 | +2.37 % |
|
| 2024-11-20 | +0.71 % |
|
| 2024-11-18 | +0.78 % |
|
| 2024-11-14 | -0.42 % |
|
| 2024-11-12 | -1.91 % |
|
| 2024-11-11 | -12.57 % |
- AbbVie Inc (NYSE:ABBV) stock fell by 12.57% after the company released disappointing results from its Phase 2 EMPOWER trials of emraclidine, an oral treatment for schizophrenia, which may have raised concerns about the drug's efficacy.
- AbbVie Inc.'s (ABBV) stock fell by 12.57% after two Phase 2 trials for emraclidine, an oral treatment for schizophrenia, failed to meet their primary endpoints, disappointing Wall Street expectations for positive results.
- AbbVie Inc (NYSE:ABBV) stock fell by 12.57% after the company reported that two Phase 2 trials for emraclidine, its oral treatment for schizophrenia, failed to meet their primary endpoints.
- AbbVie (ABBV) stock fell by 12.57% following the announcement that two Phase 2 trials of its schizophrenia treatment emraclidine failed to meet their primary endpoints.
- AbbVie Inc. shares plunged over 12% after two mid-stage trials for its schizophrenia drug, emraclidine, failed to show significant improvement compared to a placebo, raising concerns about its recent $8.7 billion acquisition of Cerevel Therapeutics and impacting investor sentiment.
|
| 2024-11-06 | -0.24 % |
|
| 2024-11-04 | -1.51 % |
|
| 2024-11-01 | -0.16 % |
|
| 2024-10-30 | +6.36 % |
|
| 2024-10-29 | -0.12 % |
|
| 2024-10-28 | +0.97 % |
|
| 2024-10-25 | -0.95 % |
|
| 2024-10-24 | +0.94 % |
|
| 2024-10-23 | -0.47 % |
|
